Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | Frankfurt | Healthcare | Biotechnology & Medical Research | €113.12B | -250.2x | 2.19 | €435 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vertex Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €112.91B | -248.9x | 2.19 | €435.20 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regeneron Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €82.41B | 20.6x | €856 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Regeneron Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €81.51B | 20.6x | €765 | -9.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Lonza Group | BATS Europe | Healthcare | Biotechnology & Medical Research | €40.86B | 67.6x | -1.46 | €566.09 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €35.39B | 26.9x | 0.84 | €182.70 | -8.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Argen-X | Brussels | Healthcare | Biotechnology & Medical Research | €32.33B | -168.5x | -3.19 | €541.60 | 5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.9% Upside | Upgrade to Pro+ | |
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €32.33B | -168.5x | -3.19 | €508.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx | Frankfurt | Healthcare | Biotechnology & Medical Research | €32.33B | -168.5x | -3.19 | €520 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
arGEN X BV | BATS Europe | Healthcare | Biotechnology & Medical Research | €32.33B | -168.5x | -3.19 | €533.20 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €24.59B | -49.1x | 0.43 | €104.10 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | Xetra | Healthcare | Biotechnology & Medical Research | €24.57B | -49.1x | 0.43 | €103.30 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biontech | Frankfurt | Healthcare | Biotechnology & Medical Research | €24.57B | -49.4x | 0.43 | €101 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Milan | Healthcare | Biotechnology & Medical Research | €19.08B | -3.5x | 0.01 | €49.64 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Vienna | Healthcare | Biotechnology & Medical Research | €19.04B | -3.5x | 0.01 | €49.71 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | Frankfurt | Healthcare | Biotechnology & Medical Research | €18.97B | -3.5x | 0.01 | €49.38 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €13.05B | 18x | 0.91 | €208.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | BATS Europe | Healthcare | Biotechnology & Medical Research | €13.04B | 18x | 0.91 | €209.19 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.76B | 21.3x | 0.2 | €29.98 | 11.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Xetra | Healthcare | Biotechnology & Medical Research | €8.66B | 129.3x | -1.62 | €39.05 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.1% Upside | Upgrade to Pro+ | |
Qiagen NV | Milan | Healthcare | Biotechnology & Medical Research | €8.64B | 129.3x | -1.62 | €38.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €8.64B | 129.3x | -1.62 | €38.96 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | BATS Europe | Healthcare | Biotechnology & Medical Research | €8.64B | 129.3x | -1.62 | €38.67 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.64B | 129.3x | -1.62 | €38.61 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.3% Upside | Upgrade to Pro+ | |
Ascendis Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €6.76B | -14.8x | -0.71 | €111 | -5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharmaceuticals | Frankfurt | Healthcare | Biotechnology & Medical Research | €5.61B | -15.3x | 1.02 | €35.92 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines | Frankfurt | Healthcare | Biotechnology & Medical Research | €5.10B | -42.7x | -0.4 | €80.76 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Denali Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €3.46B | -9.3x | 0.05 | €24.47 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €3.17B | -17.4x | -0.89 | €45.80 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Iovance Biotherapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €2.92B | -6.3x | -0.3 | €10.05 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |